SLC5A2 and heart failure: Treatment with an SGLT2 inhibitor was shown to reduce the risk of cardiovascular death or hospitalization for heart failure (HR, 0.77; 95% CI [0.72–0.82]), with an NNT of 25 (20–31) over a weighted mean of 23 months’ follow-up.